A study of tildrakizumab for genital psoriasis
Treatments studied
Part of Skin clinical trials.
This trial tests whether tildrakizumab, a biologic medicine, can help people with psoriasis that affects their genital area. It aims to see if the drug reduces symptoms like redness and scaling in those sensitive regions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriasis that also affects your genitals, and a doctor confirmed it's moderate to severe (score of 3 or higher).
- You have at least 1% of your body (excluding genitals) covered with psoriasis plaques.
- You are 18 to 99 years old.
- Your doctor has decided you need a systemic biologic therapy, and tildrakizumab is the specific anti-IL23p19 medicine chosen for you.
- You have not used tildrakizumab before.
- You have not taken any experimental treatment in the last 3 months.
- You are willing to fill out questionnaires about your symptoms and quality of life.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
This trial studies how the immune system responds in adults with moderate-to-severe psoriasis when receiving tildrakizumab. The goal is to better understand treatment effects and immune changes, which may help improve care for people with psoriasis.
This study looks at how well tildrakizumab works for people with moderate-to-severe plaque psoriasis who are starting this treatment through a support program in Canada. Researchers want to see how it affects your symptoms and daily life.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.
Hear when a new Genital Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.